Patents by Inventor Masafumi Matsuo

Masafumi Matsuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10553845
    Abstract: According to one embodiment, a battery module includes a plurality of batteries and a module housing. The module housing accommodates the plurality of batteries. The module housing is configured by connecting a plurality of cases in a first direction. At least one of the plurality of cases includes a vacuum pad adsorption region which is on an end surface in a second direction intersecting the first direction and on which a vacuum pad is adsorbable.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 4, 2020
    Assignee: Kabushiki Kaisha Toshiba
    Inventors: Makoto Nagasato, Tatsumi Matsuo, Norio Shimizu, Masafumi Ebisawa, Shinichiro Kosugi, Masahiro Sekino
  • Publication number: 20190375717
    Abstract: A production method of a compound represented by the formula [I]: or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
    Type: Application
    Filed: July 28, 2017
    Publication date: December 12, 2019
    Inventors: Takahisa Motomura, Masafumi Inoue, Hirotsugu Ito, Takuya Matsuo, Koichi Suzawa, Hiroshi Yamamoto, Tsubasa Takeichi, Yasuyuki Kajimoto, Takashi Inaba, Takao Ito, Takahiro Yamasaki, Yukishige Ikemoto
  • Patent number: 10174319
    Abstract: Insertion of variant exons of CD44 gene of cancer stem cells into its mRNA is inhibited whereupon the cancer stem cells lose their properties so that they are rendered sensitive to anticancer agents and radiation, possibly leading to cancer treatment. A drug for cancer treatment, comprising an antisense oligonucleotide capable of inducing skipping of variant exon(s) of CD44 gene to thereby increase expression of normal CD44 mRNA, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof. An oligonucleotide of 20-23 bp having the entirety or a part of any one of the nucleotide sequences as shown in SEQ ID NOS: 1 to 19, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof. A drug for inducing skipping of at least one variant exon selected from the group consisting of variant exons 8, 9 and 10 of CD44 gene, comprising the above-described oligonucleotide, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 8, 2019
    Assignees: KNC LABORATORIES CO., LTD., KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Masafumi Matsuo, Seiji Matsuda
  • Patent number: 9657050
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 23, 2017
    Assignees: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Patent number: 9657049
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 23, 2017
    Assignees: Orphan Disease Treatment Institute Co., Ltd., Daiichi Sankyo Company, Limited
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Publication number: 20170137810
    Abstract: Insertion of variant exons of CD44 gene of cancer stem cells into its mRNA is inhibited whereupon the cancer stem cells lose their properties so that they are rendered sensitive to anticancer agents and radiation, possibly leading to cancer treatment. A drug for cancer treatment, comprising an antisense oligonucleotide capable of inducing skipping of variant exon(s) of CD44 gene to thereby increase expression of normal CD44 mRNA, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof. An oligonucleotide of 20-23 bp having the entirety or a part of any one of the nucleotide sequences as shown in SEQ ID NOS: 1 to 19, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof. A drug for inducing skipping of at least one variant exon selected from the group consisting of variant exons 8, 9 and 10 of CD44 gene, comprising the above-described oligonucleotide, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof.
    Type: Application
    Filed: May 13, 2015
    Publication date: May 18, 2017
    Applicants: KNC LABORATORIES CO., LTD., KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Masafumi MATSUO, Seiji MATSUDA
  • Patent number: 9358246
    Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 7, 2016
    Assignees: Microbial Chemistry Research Foundation, The University of Tokyo
    Inventors: Ryoichi Matsuda, Masataka Shiozuka, Akira Wagatsuma, Yoshikazu Takahashi, Daishiro Ikeda, Yoshiaki Nonomura, Masafumi Matsuo, Atsushi Nishida
  • Patent number: 9241929
    Abstract: An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: January 26, 2016
    Inventors: Masatoshi Hagiwara, Masafumi Matsuo, Naoyuki Kataoka, Atsushi Nishida
  • Patent number: 9243026
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: January 26, 2016
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Publication number: 20160002636
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Applicants: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi MATSUO, Yasuhiro Takeshima, Makoto Koizumi
  • Publication number: 20150005249
    Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Inventors: Ryoichi Matsuda, Masataka Shiozuka, Akira Wagatsuma, Yoshikazu Takahashi, Daishiro Ikeda, Yoshiaki Nonomura, Masafumi Matsuo, Atsushi Nishida
  • Publication number: 20140316123
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 23, 2014
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Patent number: 8719650
    Abstract: Provided are a self-diagnosis system and a test circuit determination method that are capable of determining normality of a test circuit which diagnoses a test target circuit. A self-diagnosis system according to an aspect of the present invention includes a test circuit including first and second diagnosis controllers which determine normality of a test target circuit by using an execution result of a test pattern in the test target circuit; and a test circuit determination unit which determines normality of the test circuit by comparing a normality determination result of the test target circuit output from the first diagnosis controller with a normal determination result of the test target circuit output from the second diagnosis controller.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: May 6, 2014
    Assignee: Renesas Electronics Corporation
    Inventor: Masafumi Matsuo
  • Patent number: 8624019
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: January 7, 2014
    Assignees: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Publication number: 20130102644
    Abstract: An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower.
    Type: Application
    Filed: June 27, 2011
    Publication date: April 25, 2013
    Inventors: Masatoshi Hagiwara, Masafumi Matsuo, Naoyuki Kataoka, Atsushi Nishida
  • Publication number: 20130090465
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: November 9, 2012
    Publication date: April 11, 2013
    Inventors: Masafumi MATSUO, Yasuhiro Takeshima, Makoto Koizumi
  • Publication number: 20130005953
    Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
    Type: Application
    Filed: August 1, 2012
    Publication date: January 3, 2013
    Inventors: Ryoichi MATSUDA, Masataka SHIOZUKA, Akira WAGATSUMA, Yoshikazu TAKAHASHI, Daishiro IKEDA, Yoshiaki NONOMURA, Masafumi MATSUO, Atsushi NISHIDA
  • Publication number: 20110264972
    Abstract: Provided are a self-diagnosis system and a test circuit determination method that are capable of determining normality of a test circuit which diagnoses a test target circuit. A self-diagnosis system according to an aspect of the present invention includes a test circuit including first and second diagnosis controllers which determine normality of a test target circuit by using an execution result of a test pattern in the test target circuit; and a test circuit determination unit which determines normality of the test circuit by comparing a normality determination result of the test target circuit output from the first diagnosis controller with a normal determination result of the test target circuit output from the second diagnosis controller.
    Type: Application
    Filed: April 14, 2011
    Publication date: October 27, 2011
    Applicant: RENESAS ELECTRONICS CORPORATION
    Inventor: Masafumi MATSUO
  • Patent number: 7902160
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: March 8, 2011
    Assignees: Nonprofit Organization Translational Research Organization of Duchenne Muscular Dystrophy, KNC Laboratories Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Publication number: 20110046360
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 24, 2011
    Applicants: Nonpro. Org. Trans. Res. Org. of Duch. Musc. Dys., KNC Laboratories Co., Ltd.
    Inventors: Masafumi MATSUO, Yasuhiro TAKESHIMA, Makoto KOIZUMI